The latest articles from BioStock
» Cereno Scientific gets rid of convertible loans
» Lipum in new collaboration with American Abzena
» Biogen's failed phase III in Alzheimer's draws Swedish sector colleague with it
» Taking control of our genes to treat diseases
» New contract partner and millions in revenue for Iconovo
Read BioStock's latest newsletter for week 11 here
Cereno Scientific repays the remaining convertible loan to European High Growth Opportunities Securitization Fund. Read more.
Nasdaq Stockholm has assigned Oncology Ventures share observation status in connection with the publication of the annual report for 2018. Oncology Venture is preparing a proposed rights issue of between SEK 60 – 100 million. To strengthen short-term financial liquidity, Oncology Venture has entered into an agreement for a bridge loan facility of a total of SEK 20 million from Trention. Read more.
Double Bond Pharmaceutical carries out a rights issue of approximately SEK 10,5 million. Read more.
Moberg Pharma has completed the recruitment of 452 patients with nail fungus into the ongoing phase III study for MOB-015 in Europe. Read more.
ObsteCare announces that the major owner Peter Mansson increases its ownership in the company and exceeds 20 percent ownership. Read more.
Besins Healthcare, specializing in hormone therapy, is establishing itself in the Nordic region. Read more.
Herantis Pharma announces changes in the number of shares and votes in the company. Read more.
SyntheticMR calls an annual general meeting on April 29. Read more.
Reports/Communiqués:
BBS-Bioactive Bone Substitutes Novo Nordisk Alligator Bioscience
News received yesterday:
Enorama Pharma will establish an internal finance function and is looking for a chief financial officer for the office in Malmö. Read more.
BioArctic commented on the decision from Nasdaq Stockholm to halt trading in BioArctic's B shares due to major price movements related to the price reaction after Eisais and Biogen completed phase III studies with aducanumab against Alzheimer's disease, which the company believes should not be confused with BioArctic's drug candidate BAN2401. Read moreThe company also announced that its partner Eisai has initiated the global confirmatory Phase III study of BAN2401 in patients with early Alzheimer's disease. Read more.
Although Alzinova commented Biogens/Eisais discontinued clinical evaluation of the drug candidate aducanumab. Read more.
A1M Pharma has initiated a phase I study of ROSgard in order to document the safety profile and pharmacokinetic properties of the drug candidate. Read more.
Cantargia has decided to carry out a directed new share issue of approximately SEK 106 million for expanded clinical investment in CAN04. Read more.
Biotech-IgG Equity has extended the subscription period for the rights issue to March 29. Read more.
Ascelia Pharma published notice on stabilization measures. Read more.
BioInvent International published a prospectus regarding a rights issue and a directed issue. Read more.
Zealand Pharma announced that Alexion Pharmaceuticals Subscription of shares in the company has been completed. Read more.
Ortivus The nomination committee published its proposal for the board and chairman. Read more.
Winners in the lunch trade: Cantargia +8,59%, Inhalation Sciences +7,38%, Invent Medic +6,94%, Enzymatica +6,05%, SenzaGen +5,09%, A1M Pharma +3,83%
Losers in the lunch trade: Cereno Scientific -8,31%, Double Bond Pharmaceutical -7,69%, Eurocine Vaccines -7,49%, Aptahem -7,08%, Alteco -6,72%, Peptonic Medical -6,52%
Index: OMXS30 -0,61%, Healthcare -0,69%
More articles from BioStock
» Follow BioStock Live STHLM live broadcast
» Immunicum's research director presented at cancer seminar with Nobel glory
» Saniona: Royalty income in sight – strengthens portfolio within eating disorders
» 2cureX expands operations to prevent cancer
» Cereno Scientific adds another top international name to its Scientific Advisory Board
[et_bloom_inline optin_id=”optin_4″]
Nasdaq Stockholm has assigned Oncology Ventures share observation status in connection with the publication of the annual report for 2018. Oncology Venture is preparing a proposed rights issue of between SEK 60 – 100 million. To strengthen short-term financial liquidity, Oncology Venture has entered into an agreement for a bridge loan facility of a total of SEK 20 million from Trention. Read more.
Double Bond Pharmaceutical carries out a rights issue of approximately SEK 10,5 million. Read more.
Moberg Pharma has completed the recruitment of 452 patients with nail fungus into the ongoing phase III study for MOB-015 in Europe. Read more.
ObsteCare announces that the major owner Peter Mansson increases its ownership in the company and exceeds 20 percent ownership. Read more.
Besins Healthcare, specializing in hormone therapy, is establishing itself in the Nordic region. Read more.
Herantis Pharma announces changes in the number of shares and votes in the company. Read more.
SyntheticMR calls an annual general meeting on April 29. Read more.
Reports/Communiqués:
BBS-Bioactive Bone Substitutes Novo Nordisk Alligator Bioscience
News received yesterday:
Enorama Pharma will establish an internal finance function and is looking for a chief financial officer for the office in Malmö. Read more.
BioArctic commented on the decision from Nasdaq Stockholm to halt trading in BioArctic's B shares due to major price movements related to the price reaction after Eisais and Biogen completed phase III studies with aducanumab against Alzheimer's disease, which the company believes should not be confused with BioArctic's drug candidate BAN2401. Read moreThe company also announced that its partner Eisai has initiated the global confirmatory Phase III study of BAN2401 in patients with early Alzheimer's disease. Read more.
Although Alzinova commented Biogens/Eisais discontinued clinical evaluation of the drug candidate aducanumab. Read more.
A1M Pharma has initiated a phase I study of ROSgard in order to document the safety profile and pharmacokinetic properties of the drug candidate. Read more.
Cantargia has decided to carry out a directed new share issue of approximately SEK 106 million for expanded clinical investment in CAN04. Read more.
Biotech-IgG Equity has extended the subscription period for the rights issue to March 29. Read more.
Ascelia Pharma published notice on stabilization measures. Read more.
BioInvent International published a prospectus regarding a rights issue and a directed issue. Read more.
Zealand Pharma announced that Alexion Pharmaceuticals Subscription of shares in the company has been completed. Read more.
Ortivus The nomination committee published its proposal for the board and chairman. Read more.
Winners in the lunch trade: Cantargia +8,59%, Inhalation Sciences +7,38%, Invent Medic +6,94%, Enzymatica +6,05%, SenzaGen +5,09%, A1M Pharma +3,83%
Losers in the lunch trade: Cereno Scientific -8,31%, Double Bond Pharmaceutical -7,69%, Eurocine Vaccines -7,49%, Aptahem -7,08%, Alteco -6,72%, Peptonic Medical -6,52%
Index: OMXS30 -0,61%, Healthcare -0,69%
More articles from BioStock
» Follow BioStock Live STHLM live broadcast
» Immunicum's research director presented at cancer seminar with Nobel glory
» Saniona: Royalty income in sight – strengthens portfolio within eating disorders
» 2cureX expands operations to prevent cancer
» Cereno Scientific adds another top international name to its Scientific Advisory Board
[et_bloom_inline optin_id=”optin_4″]